Corvus Pharmaceuticals (CRVS) Change in Acquisitions & Divestments (2015 - 2026)

Corvus Pharmaceuticals' Change in Acquisitions & Divestments history runs 12 years deep, the most recent figure standing at $17.0 million for Q1 2026.

• In Q1 2026, Change in Acquisitions & Divestments rose 41.67% year-over-year to $17.0 million; the TTM figure through Mar 2026 stood at $89.1 million (up 78.26% YoY), while the FY2025 annual figure was $84.1 million, up 97.34% from the prior year.
• Change in Acquisitions & Divestments for Q1 2026 stood at $17.0 million, down from $24.3 million in the prior quarter.
• The five-year high for Change in Acquisitions & Divestments was $28.5 million in Q3 2025, with the low at $810000.0 in Q1 2022.
• The 5-year median for Change in Acquisitions & Divestments is $15.4 million (2022), against an average of $14.7 million.
• The sharpest annual moves came in 2022 and 2023: Change in Acquisitions & Divestments slumped 90.08% in 2022, then surged 2088.27% in 2023.
• Corvus Pharmaceuticals' Change in Acquisitions & Divestments stood at $15.4 million in 2022, then tumbled by 40.85% to $9.1 million in 2023, then soared by 56.73% to $14.3 million in 2024, then surged by 70.41% to $24.3 million in 2025, then plunged by 30.18% to $17.0 million in 2026.
• Business Quant data shows CRVS's Change in Acquisitions & Divestments at $17.0 million in Q1 2026, $24.3 million in Q4 2025, and $28.5 million in Q3 2025.